Stifel reiterates Buy on Definium Therapeutics stock, $60 target

Definium Therapeutics Inc. remains a Buy recommendation from Stifel with a $60.00 price target, according to the latest update on Investing.com. Currently trading at $39.07, the stock has seen a 12% decline over the past week but has climbed 322% year-to-date. Analysts express optimism, with a consensus Strong Buy rating and targets ranging from $52 to $90.

Stifel recently met with CEO Rob Barrow to discuss upcoming catalysts, such as a second phase 3 GAD readout anticipated later in the month. The firm highlighted clinical efficacy in their late-stage studies, particularly the Panorama study featuring a 50µg arm to enhance rigor and reduce bias. The primary success criterion is demonstrating a statistically significant difference between the 100µg dose and placebo.

Definium plans to file jointly for MDD and GAD indications, contingent on a positive pre-NDA meeting. Financially, DFTX holds more cash than debt, per InvestingPro's assessment. The company's DT120 drug, an orally-disintegrating tablet for generalized anxiety disorder, showed positive results in its Phase 3 Voyage trial, meeting primary and secondary efficacy endpoints.

This outcome has led to an increased price target from Canaccord Genuity (from $58 to $64) and a Buy rating from BofA Securities (currently at $75). Stifel's decision to maintain its Buy rating with a $60 target underscores continued confidence in Definium's drug candidate and its potential impact on treating brain health disorders.